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ABSTRACT
Intrinsic cross-resistance to inhibition of different signaling pathways may 
hamper development of combinatorial treatments in melanoma, but the relative 
frequency of this phenotype and the strategies to overcome this hurdle remain 
poorly understood. Among 49 BRAF-mutant melanoma cell lines from patients not 
previously treated with target therapy, 21 (42.9%) showed strong primary resistance 
(IC50 > 1 μM) to a BRAFV600E inhibitor. Most of the BRAF-inhibitor-resistant cell 
lines showed also strong or intermediate cross-resistance to MEK1/2- and to PI3K/
mTOR-specific inhibitors. Primary cross-resistance was confirmed in an independent 
set of 23 BRAF-mutant short-term melanoma cell cultures. MEK1/2 and PI3K/mTOR 
co-targeting was the most effective approach, compared to BRAF and PI3K/mTOR 
dual blockade, to counteract primary resistance to BRAF inhibition and the cross-
resistant phenotype. This was shown by extensive drug interaction analysis, tumor 
growth inhibition assays in-vivo, p-ERK and p-AKT inhibition, promotion of melanoma 
apoptosis, apoptosis-related protein modulation, activation of effector caspases and 
selective modulation of genes involved in melanoma drug resistance and belonging 
to the ERK/MAPK and PI3K/AKT canonical pathways. Compared to co-targeting 
of mutant BRAF and PI3K/mTOR, the association of a MEK1/2 and a PI3K/mTOR 
inhibitor was more effective in the activation of Bax and of caspase-3 and in the 
induction of caspase-dependent melanoma apoptosis. Furthermore Bax silencing 
reduced the latter effects. These results suggest that intrinsic resistance to BRAF 
inhibition is frequently associated with primary cross-resistance to MEK and PI3K/
mTOR blockade in BRAF-mutant melanoma and provide pre-clinical evidence for a 
combinatorial approach to counteract this phenotype.
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INTRODUCTION
Inhibitors of BRAFV600E have changed the clinical 
management of patients with BRAF-mutant advanced 
melanoma, since significant improvements in progression-
free survival (PFS) and in overall survival (OS) have been 
reported in Phase 3 trials [1–2]. These inhibitors can 
induce objective responses or stabilization of disease in 
a high fraction of patients [2–3], although relapse occurs 
due to adaptive [4] or acquired [5] resistance mechanisms. 
In addition, ~20% of patients show primary/intrinsic 
resistance to BRAF inhibitors and experience tumor 
progression at first assessment during therapy [2–3]. 
Lack of response has been observed even in trials with 
MEK inhibitors as Trametinib and Selumetinib/AZD6244 
[6–7], pointing to primary resistance also to the targeting 
of MEK. To counteract resistance to BRAF inhibitors, 
several clinical trials based on combinatorial targeting 
of BRAF and MEK have been carried out recently, and 
results have indicated a significant improvement in PFS 
and (in one study) in OS, compared to monotherapy with 
the BRAF inhibitor alone [8–10]. However, strikingly, in 
all these studies ~30% of the patients showed progressive 
disease at 6 months of treatment [8–10], pointing to the 
potential role of cross-resistance mechanisms. Indeed, 
primary cross-resistance to BRAF and MEK inhibitors has 
been documented in a subset of melanomas, where it is 
related to the MITF profile [11–13], and in cell lines [14]. 
In the attempt to address all these limitations 
associated with targeting of a single (MAPK) pathway, 
several pre-clinical studies have suggested that combi-
natorial targeting of MAPK and PI3K/mTOR intracellular 
pathways may be a potential approach to improve target 
therapy of melanoma and to overcome resistance and 
cross-resistance mechanisms [14–17]. However, key 
questions to be answered are whether BRAF-mutated 
melanomas, with intrinsic resistance to BRAF and/or 
MEK inhibitors, also have primary cross-resistance to 
PI3K/mTOR inhibitors and which is the frequency of such 
cross-resistant phenotype. A second issue to be addressed 
is whether combinatorial targeting of different signaling 
pathways is effective even in the tumors with primary 
cross-resistance. 
Recently, we observed instances of primary cross-
resistance to a MEK1/2 (AZD6244) and to a dual PI3K/
mTOR (BEZ235) inhibitor in some melanoma cell lines 
(18). Starting from this initial evidence, in this study we 
assessed responsiveness to BRAFV600E-, MEK1/2-, 
dual PI3K/mTOR- and dual mTORC1/2-specific inhibitors 
in 49 BRAF-mutant melanoma cell lines and in an 
independent set of 23 BRAF-mutant short-term melanoma 
cell cultures, all isolated from patients never treated with 
target therapy. Among cell lines with strong intrinsic 
resistance to the BRAF inhibitor (IC50 > 1 μM, n = 21), 
81% (seventeen) showed strong or intermediate cross-
resistance to the MEK1/2- and the PI3K/mTOR-specific 
inhibitors. Extensive drug interaction analysis on all 49 cell 
lines and mechanistic studies in cross-resistant cell lines 
indicated that co-targeting of MEK1/2 and PI3K/mTOR, 
in-vitro and in-vivo, was a more effective combinatorial 
treatment, compared to co-targeting of BRAF and PI3K/
mTOR, to counteract the primary cross-resistant phenotype.
RESULTS
Primary resistance to BRAFV600E inhibition 
is associated with cross-resistance to MEK1/2 
and PI3K/mTOR inhibitors in BRAF-mutant 
melanoma cells
We used 49 BRAF-mutant melanoma cell lines 
isolated from surgical specimens of patients not previously 
treated with BRAFV600E inhibitors, nor with any 
other target-specific inhibitor, to test responsiveness to 
BRAFV600E (PLX4720), MEK1/2 (AZD6244), dual 
PI3K/mTOR (BEZ235) and dual mTORC1/2 (AZD8055) 
inhibitors (Figure 1A). Three susceptibility groups were 
defined by ranking cell lines based on their IC50 values for 
PLX4720. Strong resistance (IC50 > 1 μM) was found in 
21/49 cell lines (42.9%, group 1), intermediate resistance 
(IC50 = 0.1 to 1 μM) and susceptibility (IC50 < 0.1 μM) to 
PLX4720 were observed in 16/49 (32.7%, group 2) and 
12/49 cell lines (24.5%, group 3), respectively (Figure 1A 
and Supplementary Table 1D for descriptive statistics). 
Seventeen out of 21 melanoma lines (marked with an 
“x” in Figure 1A) classified in group 1, showed either 
strong or intermediate primary resistance to MEK1/2 and 
PI3K/mTOR inhibitors. Strong or intermediate cross-
resistance to PI3K/mTOR inhibitors was also found in 
11/16 cell lines in group 2, while only two cell lines in 
group 3 (PLX4720 susceptible) showed strong resistance 
to the PI3K/mTOR inhibitors (Figure 1A). Hierarchical 
clustering of log-transformed and normalized IC50 values 
confirmed the existence of distinct subsets of cell lines 
with cross-resistance to all inhibitors or susceptible to 
all of them (Figure 2A). Spearman correlation analysis 
of IC50 values for all six possible combinations of four 
inhibitors showed that all the susceptibility profiles were 
significantly correlated (Figure 2B). 
To validate these findings, an independent panel of 
short-term melanoma cell cultures (all tested between the 
third and fifth in-vitro passage), obtained from 23 BRAF-
mutant metastatic specimens of patients not previously 
treated with target-specific inhibitors, was used to test 
responsiveness to the same set of inhibitors. The same 
classification into three subsets based on ranking of 
PLX4720 IC50 values was applied. We found that 6/6 
PLX4720-resistant melanoma cell cultures (group 1) 
showed strong (i.e. IC50 > 1 μM) or intermediate 
(i.e. IC50 > 0.1 μM) cross-resistance to MEK1/2 and 
PI3K/mTOR inhibitors, and 11/13 cultures in group 2 
(intermediate resistance to PLX4720) showed also strong 
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Figure 1: Responsiveness to BRAF-V600E-, MEK1/2- or PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma 
cell lines. (A) Susceptibility to PLX4720 (BRAFV600E inhibitor), AZD6244 (MEK1/2 inhibitor), BEZ235 (dual PI3K/mTOR inhibitor) 
and AZD8055 (dual mTORC1/2 inhibitor), shown as IC50 values (μM), was assessed by a 72 h MTT assay in a panel of 49 melanoma 
cell lines. IC50 values obtained through non linear regression analysis of twelve-point dose-response curves spanning 4 logs of inhibitor 
concentrations. Melanomas were distinguished into three groups after ranking based on PLX4720 IC50 values (group 1: IC50 > 1 μM; group 
2: IC50 > 0.1 μM but < 1 μM; group 3: IC50 ≤ 0.1 μM). (B) Color code used for highlighting differences in IC50 values in panel A.
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or intermediate cross-resistance to PI3K/mTOR inhibitors 
(Figure 3A). As a control, 10 short-term melanoma cell 
cultures from tumors with wt BRAF were characterized 
for responsiveness to the four inhibitors. As expected [19], 
all the BRAF wt melanoma cell cultures were strongly 
resistant to PLX4720, but some of them also showed 
strong resistance to the MEK1/2 or to the PI3K/mTOR 
inhibitors (Figure 3B). Interestingly, the melanoma cell 
culture Me_cc135, with intermediate cross-resistance, was 
isolated from a specimen of a patient who subsequently 
(4.4 months after Me_cc135 isolation) was treated with a 
BRAF inhibitor and underwent progressive disease after 
two cycles of therapy. In contrast, melanoma cell cultures 
Me_cc111 and Me_cc128, with a cross-susceptible 
phenotype, were isolated from patients who subsequently 
(75.4 and 2.8 months, after Me_cc111 and Me_cc128 
isolation, respectively) were treated with the association 
of a BRAF and a MEK inhibitor or in monotherapy with 
a MEK inhibitor and experienced a partial response or a 
complete response, respectively. 
Twelve days clonogenic assays on representative 
cell lines (Me43 and Me71) and short-term melanoma 
cell cultures (Me_cc117 and Me_cc128) from the 
cross-susceptible group 3 (Supplementary Figure 1A), 
indicated a strong suppression of melanoma growth by 
AZD6244, PLX4720, BEZ235 and AZD8055, often 
detected at the lowest inhibitor dose (0.1 μM). In contrast, 
clonogenic assays on representative cell lines (Me35, Me6, 
Me13) and short-term melanoma cell cultures (Me_cc102) 
from group 1 (Supplementary Figure 1B) showed a partial 
or markedly reduced inhibitory effect by AZD6244 (on 
Me35 and Me_cc102), by PLX4720 (on Me35, Me6, Me13 
and Me_cc102), and by AZD8055 (on Me35, Me13 and 
Me_cc102). BEZ235 exerted a reduced inhibitory effect 
on Me35, even at the highest dose, in agreement with the 
high IC50 value in this cell line (Supplementary Figure 1B). 
Taken together, these assays confirmed that cell lines and 
short-term melanoma cell cultures in group 1 showed 
markedly reduced responsiveness to multiple inhibitors. 
The panel of 49 melanoma cell lines shown in 
Figure 1, was further characterized for several molecular or 
phenotypic features associated with drug resistance [20–23], 
but no significant association was found, between the drug 
susceptibility groups and: a) the PTEN, MDM4 and MDM2 
expression levels; b) the constitutive p-ERK, p-AKT and 
p-S6 levels (Supplementary Table 1A–1C and 1E–1G). 
Figure 2: Responsiveness profiles of BRAF-mutant human melanoma cell lines to BRAFV600E-, MEK1/2-, and PI3K/
mTOR-specific inhibitors are significantly correlated. (A) Hierarchical clustering of normalized and Log-transformed IC50 values 
for the indicated inhibitors in 49 melanoma cell lines. Each IC50 value (as listed in Figure 1) was normalized against the median IC50 value 
of each inhibitor in the whole panel. (B) Spearman correlation analysis of IC50 values for each of the six possible combinations of the four 
inhibitors in the whole panel of melanoma cell lines. 
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Figure 3: Responsiveness to BRAF-V600E-, MEK1/2- or PI3K/mTOR-specific inhibitors in short-term melanoma cell 
cultures. (A, B) Susceptibility to PLX4720, AZD6244, BEZ235 and AZD8055, shown as IC50 values (μM), was assessed as described 
in the legend to Figure 1, in a panel of 33 melanoma cell cultures (Me_cc) bearing mutant BRAF (n = 23, A) or wt BRAF (n = 10, B). 
Melanoma cell cultures were established from surgical specimens of lymph node metastases and were tested between the third and fifth 
in-vitro passage. Short term melanoma cell cultures from BRAF-mutant lesions were distinguished into three groups after ranking based 
on PLX4720 IC50 values as in Figure 1. BRAF genotype: mut: BRAFV600E; mut*: BRAFV600K WT. BRAF wild type. IC50 values were 
highlighted by the color code indicated in Figure 1B.
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We also assessed the MITF phenotype of the cell lines and 
short-term melanoma cell cultures, as either high or low 
expression of this transcription factor has been associated 
with drug resistance in melanoma [11–13]. We found that 
melanoma cell lines retained the MITF phenotype of the 
corresponding lesions, but both MITFhi and MITFlo cell 
lines and short term cultures were found in each of the 
three susceptibility groups (data not shown). 
Taken together, these results indicated that intrinsic 
resistance to BRAFV600E inhibition can be frequently 
associated with cross-resistance to MEK1/2 and/or PI3K/
mTOR inhibitors in BRAF-mutant melanoma cells. 
Co-targeting of MAPK and PI3K/mTOR 
pathways in melanoma cells with a primary 
cross-resistant phenotype has synergistic effects 
in vitro and anti-tumor activity in vivo
To test whether combinatorial targeting of MAPK 
and PI3K/mTOR pathways could overcome primary 
cross-resistance, we performed drug interaction analysis 
by the Chou-Talalay method [24]. To this end, 49 cell 
lines belonging to the three susceptibility groups were 
treated with AZD6244-BEZ235, or PLX4720-BEZ235 or 
AZD6244-AZD8055 associations. For each association 
of inhibitors, twelve different combinations of doses 
(indicated at the top of Figure 4A) were evaluated, 
yielding a 1,764-point drug interaction matrix (49 cell 
lines by 36 drug combinations). Strong synergistic 
effects, documented by CI values < 0.3 (Figure 4A and 
4B for color codes and meaning of CI values and 
Supplementary Table 2 for primary data), were achieved 
on almost all cell lines from group 2 and 3. Interestingly, 
strong synergism was observed at most drug dosing 
combinations, against 20/21 melanoma cell lines in 
group 1 (Figure 4A), including 16/17 lines with the cross-
resistant phenotype (Figure 4A, arrows). By clonogenic 
assays (Supplementary Figure 2A, 2B) AZD6244-BEZ235 
and PLX4720-BEZ235 combinatorial treatments exerted a 
strong inhibitory effect on melanoma growth not only on 
two cell lines from group 3 (Me43 and Me71), but also on 
three cell lines from group 1 (Me35, Me6, Me13). 
Figure 4: Synergistic drug interaction by co-targeting of MAPK and PI3K/mTOR pathways in melanoma cell lines. 
(A) Drug interaction analysis by the association of AZD6244 and BEZ235, PLX4720 and BEZ235, or AZD6244 and AZD8055 was carried 
out by the Chou-Talalay method in three groups of melanoma cell lines with different responsiveness to PLX4720 (Group 1, Group 2 and 
Group 3 as defined in Figure 1). Results for each of the indicated combinations of inhibitors (drug doses listed at the top of the Figure), for 
each cell line, are shown as Combination Indexes (CI) values by a color code shown in panel (B) Arrows: cell lines (n = 17) with a strong 
cross-resistant phenotype as in Figure 1. Blue lines: Wilcoxon matched pair test of CI values observed by AZD6244-BEZ235 vs. PLX4720-
BEZ235 combinations having equivalent drug dosing. **p < 0.01. (B) color code for CI values, range of values and corresponding meaning 
(antagonism, additivity, synergy) according to ref. 24. Red indicates antagonism, green indicates synergism. 
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In addition, the AZD6244-BEZ235 combination 
induced a significantly stronger synergistic effect (lower 
CI values) against the whole panel of 49 melanoma cell 
lines compared to PLX4720-BEZ235, in three out of 
nine experimental conditions where both AZD6244 and 
PLX4720 were present at equivalent doses (Figure 4A, 
statistical comparisons highlighted by blue lines and 
asterisks). 
 In addition to a combination index matrix, the drug 
interaction analysis yielded also a 1,764-point Fraction 
Affected (FA) matrix (Supplementary Figure 3A, 3B 
for color coding of FA values and Supplementary Table 
3 for primary data). Analysis of the FA matrix led to 
two main conclusions. First, combinatorial treatment 
with AZD6244-BEZ235 or PLX4720-BEZ235, but to a 
much lesser extent with AZD6244-AZD8055, allowed to 
achieve FA values > 0.50, or even > 0.70, on most cross-
resistant cell lines in group 1. Second, and most relevant, 
in each of the 9 matched drug combinations (identified by 
matched symbols at bottom of Supplementary Figure 3A) 
where AZD6244 and PLX4720 were used at equivalent 
doses, AZD6244-BE235 induced significantly higher FA 
values compared to PLX4720-BEZ235 on the 21 cell lines 
in group 1, characterized by strong primary resistance to 
PLX4720 and by frequent cross-resistance (Supplementary 
Figure 4A, 4B for statistical analysis). 
We then compared anti-tumor activity in-vivo of 
AZD6244-BEZ235 and PLX4720-BEZ235 combinatorial 
treatments. To this end, we established a SCID mouse 
model based on s.c. xenograft of a cell line from group 1 
(Me13). This cell line was characterized by strong primary 
resistance to PLX4720 (IC50 > 1 μM) and by intermediate 
resistance to AZD6244 and BEZ235 (IC50 > 0.1 μM). Both 
treatments exerted a significant inhibitory effect on tumor 
growth, compared to control animals treated with vehicle, 
but the AZD6244-BEZ235 association was signifi-
cantly more effective than PLX4720-BEZ235 treatment 
(Supplementary Figure 5). Moreover, no evident signs of 
treatment-related toxicity were observed (data not shown).
Taken together, the in-vitro and in-vivo experiments 
indicated that co-targeting of MEK1/2 and PI3K/mTOR 
has improved anti-tumor activity compared to co-targeting 
of mutant BRAF and PI3K/mTOR even in melanoma cells 
with an intrinsic cross-resistant phenotype. 
MEK1/2 and PI3K/mTOR co-targeting is more 
effective than BRAF and PI3K/mTOR dual 
blockade in inhibition of signaling molecule 
phosphorylation in PLX4720-resistant and in 
cross-resistant melanoma cell lines
Changes in the phosphorylation status of ERK, AKT 
and S6 by the combinatorial treatments were assessed in 
three cell lines from group 1 (Me13, Me6 and Me79). 
Me13 and Me6 have a higher IC50 for PLX4720 than 
for AZD6244, therefore PLX4720 was used at a higher 
dose compared to AZD6244 (see legend to Figure 5). In 
these normalized conditions, the AZD6244-BEZ235 and 
AZD6244-AZD8055 associations were more effective 
than PLX4720-BEZ235 at inhibiting p-ERK in Me13 
after O/N treatment, and AZD6244-BEZ235 was the 
most effective treatment as suppressing p-ERK in 
Me6 (Figure 5). AZD6244-BEZ235 was also the most 
effective treatment at inhibiting p-AKT in Me13 and 
Me6 (Figure 5). All three treatments showed similar 
inhibitory activity on p-S6 (Figure 5). Enhanced p-ERK 
inhibition by AZD6244-BEZ235 and AZD6244-AZD8055 
compared to PLX4720-BEZ235 were observed also 
on Me79, a strongly cross-resistant cell line in group1 
(Figure 5) as well as on Me71, a cell line from group 3 
susceptible to all inhibitors (Supplementary Figure 6). 
The enhanced suppression of p-ERK by AZD6244-
BEZ235 and AZD6244-AZD8055 treatments, compared 
to PLX4720-BEZ235, was confirmed even after a shorter 
(4 h) treatment on melanoma cell lines from group 1 
(Me13 and Me79, Supplementary Figure 7). At 4 h of 
treatment, AZD6244-BEZ235 and PLX4720-BEZ235 
were effective in suppressing p-AKT on Me13 and Me79, 
while inhibition of pS6 by the combinatorial treatments 
was strongly reduced on Me13 and not observed on Me79 
compared to the effects detected on the same cell lines after 
O/N treatment (see Supplementary Figure 7 vs. Figure 5). 
Enhanced inhibition of p-ERK and p-AKT by AZD6244-
BEZ235 compared to PLX4720-BEZ235, and to control 
animals treated with vehicle, was also observed in-vivo, 
as indicated by a reduced staining for p-ERK and p-AKT 
in melanoma cells from neoplastic nodules removed after 
the last administration of inhibitors (Figure 6A, 6B and 
Supplementary Figure 8 for quantitative analysis). 
Taken together, these results indicated that the asso-
ciation of MEK1/2 and PI3K/mTOR inhibitors induces 
a more effective inhibition of p-ERK at both early and 
late time points compared to BRAF and PI3K/mTOR dual 
blockade, in PLX4720-resistant melanoma cells and even 
in cell lines with a cross-resistant phenotype. 
Enhanced apoptotic response in melanoma cells 
with a cross-resistant phenotype by co-targeting 
of MEK1/2 and PI3K/mTOR
The most significant effect of AZD6244-BEZ235, 
compared to PLX4720-BEZ235 and to AZD6244-AZD8055, 
was a reciprocal shift in the sub-G1 and G1 fractions, while 
S and G2M phases of the cell cycle were not differentially 
affected, as documented by DNA content analysis 
(Supplementary Figure 9) in representative melanoma cell 
lines from the three PLX4720 susceptibility groups. This 
result was consistent with enhanced induction of cell death 
by AZD6244-BEZ235. By annexin-V/PI staining assays we 
compared extent of apoptosis induced by single inhibitors 
and by the three combinatorial treatments on representative 
cell lines from the three groups. To this end, inhibitors 
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Figure 5: Inhibition of p-ERK and p-AKT by combinatorial treatments in melanoma cells with intrinsic resistance 
to PLX4720. Three melanoma cell lines from group 1 (Me13, Me6 and Me79) were treated O/N with AZD6244, BEZ235, PLX4720, 
AZD8055, or the indicated combinations, and then assessed by western blot for inhibition of relevant signaling molecules. Drug doses for 
Me13 and Me6 were: AZD6244: 0.1 μM; BEZ235: 0.1 μM; PLX4720: 0.5 μM; AZD8055: 0.1 μM. Drug doses for Me79 were 0.5 μM for 
all inhibitors.
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Figure  6:  Inhibition  of  p-ERK  and  p-AKT  in-vivo by combinatorial treatments in a PLX4720-resistant cell line. 
Immunohistochemistry analysis by staining with anti-p-ERK (A) and anti-pAKT (B) antibodies of tumor nodules (images of nodules from 
two animals are shown for each signaling molecule) removed after the last administration of inhibitors (day 31), from control mice (vehicle) 
and from mice treated with the association of AZD6244-BEZ235 or of PLX4720-BEZ235, as described in the legend to Supplementary 
Figure 5. Insets, higher magnification of a representative area of each panel highlighting the extent of staining for p-ERK and p-AKT in 
melanoma cells. Original magnification, 20x. 
Figure 7: Combinatorial treatments promote melanoma apoptosis. Seven melanoma cell lines (representative of the three 
susceptibility groups) were treated with AZD6244, BEZ235, PLX4720, AZD8055 or the indicated combinations of inhibitors for 72 h, and 
then apoptosis was assessed by Annexin-V/PI assay. Each histogram is the sum of early (annexin-V+/PI–, grey) and late (annexin-V+/ PI+, 
white) apoptosis values. Extent of primary necrosis (% Annexin-V-/PI+ cells) was always < 5% in control cells and in any of the treatments. 
Concentrations of inhibitors: Group 1 (Me6 and Me13): AZD6244 0.1 μM, BEZ235 0.1 μM, PLX4720 0.5 μM, AZD8055 0.3 μM; Group 1 
(Me79): 0.5 μM for all inhibitors; Group 2 (Me63, Me17, Me45): AZD6244 0.05 μM, BEZ235 0.1 μM, PLX4720 0.1 μM, AZD8055 
0.1 μM; Group 3 (Me 71): AZD6244 0.05 μM, BEZ235 0.1 μM, PLX4720 0.1 μM, AZD8055 0.02 μM. Statistical analysis by ANOVA and 
SNK test. ***p < 0.001.
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doses were tailored to each melanoma group based on the 
different IC50 values (see legend, Figure 7). By annexin-V/
PI stainings we compared the extent of apoptosis induced 
by the three combinatorial treatments. AZD6244-BEZ235 
was found to be the most effective association, not only 
against representative cell lines from groups 2 and 3 
(Figure 7), but even against melanoma cells with the strong 
(Me79) or intermediate (Me13) cross-resistant phenotype 
in group 1 (Figure 7). Further apoptosis assays were carried 
out by comparing the three combinatorial treatments on all 
49 melanoma cell lines. These experiments confirmed that 
AZD6244-BEZ235 was more effective than PLX4720-
BEZ235 against the cell lines in group 1 and group 2 
(Supplementary Figure 10A). 
By protein arrays experiments we found that 
AZD6244-BEZ235 was more effective than PLX4720-
Figure 8: Modulation of pro- and anti-apoptotic proteins by combinatorial  treatments. Expression of apoptosis-related 
proteins, by protein array screening, in Me13, Me41 and Me71 cells (representing each of three different susceptibility groups defined in 
Figure 1) at 48 hours of treatment with or without AZD6244 (A62), BEZ235 (BEZ), PLX4720 (PLX), AZD8055 (A80) and the combinations 
AZD6244-BEZ235 (A + B), PLX4720-BEZ235 (P + B) and AZD6244-AZD8055 (A + A). Inhibitors concentrations, tailored to the IC50 
values of the three susceptibility groups, were: Group 1 (Me13): AZD6244 0.1 μM, BEZ235 0.1 μM, PLX4720 0.5 μM, AZD8055 0.3 μM; 
Group 2 (Me41): AZD6244 0.05 μM, BEZ235 0.1 μM, PLX4720 0.1 μM, AZD8055 0.1 μM; Group 3 (Me 71): AZD6244 0.05 μM, 
BEZ235 0.1 μM, PLX4720 0.1 μM, AZD8055 0.02 μM. Statistical analysis by ANOVA and SNK test. ***p < 0.001; **p < 0.01; *p < 0.05.
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BEZ235 at enhancing expression of the Bax protein, a pro-
apoptotic Bcl-2 family member, and at downregulating 
the inhibitor of apoptosis c-IAP1 in melanoma cells from 
the three groups and of livin/ML-IAP in melanoma cells 
from group 1 and 2 (Figure 8). By staining Me6 melanoma 
cells with the 6A7 antibody, recognizing conformational 
changes of Bax, one of the early steps in the induction 
of apoptosis, we found a significantly increased fraction 
of Bax+ melanoma cells upon treatment for 24 h with 
AZD6344-BEZ235 compared to PLX4720-BEZ235 and 
to AZD6244-AZD8055 (Figure 9A, 9B). Silencing of 
Bax in Me6, by siRNA (Figure 9C), significantly reduced 
activation of caspase-3 and (Figure 9D, 9E) and apoptosis 
(Figure 9F) upon treatment with AZD6344-BEZ235 or 
PLX4720-BEZ235. 
On the basis of these results, we then tested whether 
co-targeting of MEK1/2 and PI3K/mTOR could lead to 
enhanced activation of effector caspases [25] on most cell 
lines, compared to the other associations. In agreement, 
AZD6244-BEZ235 combination was more effective than 
PLX4720-BEZ235 and AZD6244-AZD8055 associations 
in inducing caspase 3/7 enzymatic activation in assays 
carried out on all 49 melanoma cell lines (Supplementary 
Figure 10B). Further assays looking at the generation 
of active, cleaved caspase-3, indicated that AZD6244-
BEZ235 was the most effective treatment, compared 
to PLX4720-BEZ235 and to AZD6244-AZD8055 in 
melanoma cells from group 3 (Me71) and from group 1 
(Me6, Me13 and Me79, Supplementary Figure 11A, 11B). 
Assessment of neoplastic nodules removed after the 
last administration of inhibitors from mice receiving 
the combinatorial treatments indicated an enhanced 
activation of caspase-3, associated with induction of 
apoptosis (TUNEL+ cells), in tumors from mice treated 
Figure 9: Role of Bax upregulation, by combinatorial treatments, in caspase-3 activation and melanoma apoptosis. 
(A, B) Me6 melanoma cells were treated for 24 h with the indicated associations of inhibitors and then stained with the Bax conformation-
specific mAb 6A7. Inhibitors doses as in Figure 7. (B) Mean of three experiments. (C) Western blot analysis for Bax at 48 h and 96 h after 
transfection with Bax-specific Smart Pool siRNA or with the corresponding negative control siRNA. (D–F) Me6 cells, transfected with 
Bax-specific Smart Pool siRNA or with the negative control siRNA, were treated at 48 h with the AZD6244-BEZ235 or PLX4720-BEZ235 
associations and analyzed at 96 h for active, cleaved caspase-3 (D, E) or for apoptosis (F). Numbers in each panel in A, D: % positive cells, 
markers set based on staining with secondary antibody only (A) or isotype control (D). Statistical analysis by ANOVA and SNK test (B) or 
two-way ANOVA and Bonferroni test (E, F). **p < 0.01, ***p < 0.001. 
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with AZD6244-BEZ235 compared to PLX4720-BEZ25 
(Supplementary Figure 12). 
In-vitro, a pan-caspase inhibitor z-VAD-fmk, but not 
the negative control z-FA-fmk, significantly reduced Me6 
cells apoptosis promoted by the combinatorial treatments, 
indicating that melanoma apoptosis was caspase-
dependent (Supplementary Figure 13A, 13B). 
Taken together, these results suggest that co-targeting 
of MEK1/2 and PI3K/mTOR, compared to BRAF and PI3K/
mTOR dual blockade, is a more effective approach to rescue 
susceptibility to caspase-dependent apoptosis in melanoma 
cells with intrinsic cross-resistant phenotype.
Selective modulation of genes in the ERK/MAPK 
and PI3K/AKT canonical pathways by MEK1/2 
and PI3K/mTOR dual blockade compared to 
BRAF and PI3K/mTOR co-targeting
Whole genome gene expression analysis was carried 
out in the PLX4720-resistant Me13 cell line treated with 
AZD6244-BEZ235, or PLX4720-BEZ235 or AZD6244-
AZD8055 associations, to identify combination-specific 
effects. To improve the statistical analysis of the results, 
three independent biological replicates for each treatment 
were analyzed. Moreover, drug doses were chosen 
according to the different IC50 values; thus, PLX4720 
was used at 0.5 μM while AZD6244 was used at 0.1 μM 
(see Materials and methods for details). Significantly 
modulated genes by each combination, identified by class 
comparison through BRB Array Tools, were subjected 
to downstream effect analysis through IPA software. 
“Cell death and survival” was the top biological function 
affected by the three combinatorial treatments, but the most 
significant P value for association with such function was 
observed for the AZD6244-BEZ235 treatment (data not 
shown). Based on Z scores > 2 or < -2, the function “cell 
death” was predicted to be increased, while the function 
“proliferation” was predicted to be decreased by the three 
combinatorial treatments (see Supplementary Table 4 for 
results on AZD6244-BEZ235 treatment). By Edwards-
VENN diagram analysis [26] combination-specific gene 
expression changes were identified (Supplementary 
Figure 14, underlined values) in addition to gene 
expression changes shared by two or even three different 
combinatorial treatments (Supplementary Figure 14, 
boxed values). Thus, AZD6244-BEZ235 upregulated 
a set of 79 genes and downregulated a different set of 
83 genes, not significantly affected by the other two 
combinatorial treatments. By canonical pathway analysis 
by IPA (Supplementary Figure 15), the specificity of each 
combinatorial treatment was revealed by two parameters: 
a) the different ranking of each of the top 15 pathways 
(based on the P value of the association of the genes with 
the pathway) and, b) the differences, among the three 
combinatorial treatments, in the fraction of significantly 
modulated genes belonging to each pathway (plotted as 
stacked bar charts in Supplementary Figure 15). Thus, 
upon combinatorial treatment with AZD6244-BEZ235, 
the two top canonical pathways affected were the “PI3K/
AKT signaling”, and the “PTEN signaling”. In contrast, 
upon melanoma treatment with PLX4720-BEZ235 or with 
AZD6244-AZD8055 these two pathways ranked third and 
second, or 15th and sixth, respectively (Supplementary 
Figure 15). 
By looking at genes belonging to three canonical 
pathways (ERK/MAPK, PI3K/AKT, and “prostate 
cancer signaling”) specific differences in the modulatory 
effects induced by the three combinatorial treatments 
were identified (highlighted by red arrows in Figure 10 
and Supplementary Figure 16A–16C). This comparison 
indicated that AZD6244-BEZ235 induced a selective 
downmodulation of several genes, including c-FOS 
(Figure 10A), recently involved in melanoma resistance 
to MAPK inhibition [13], and p90RSK encoding for 
proteins that phosphorylate CREB transcription factors 
[27–28], also involved in melanoma resistance to 
MAPK inhibition [13]. The preferential downmodulation 
of c-FOS by AZD6244-BEZ235, compared to the 
effects of the other associations of inhibitors, was 
confirmed by qPCR (Supplementary Figure 17A). 
AZD6244-BEZ235, but not PLX4720-BEZ235, 
downmodulated the anti-apoptotic gene Bcl-2 and 
the mTOR interactor 4EBP1 (Figure 10B), as well as 
β catenin, a gene that impairs T cell-mediated immune 
response in melanoma [29], and LEF-1 [30] a β catenin 
interacting partner (Supplementary Figure 16B, 16C). 
The latter two genes are upstream of cyclin D1, a gene 
being more strongly inhibited (FC = −3.85) by AZD6244-
BEZ235, compared to PLX4720-BEZ235 (FC = −2.17). 
β catenin downmodulation by AZD6244-BEZ235 
treatment was confirmed by qPCR (data not shown). By 
immunohistochemistry in neoplastic nodules removed 
after the last administration of inhibitors, a reduced 
staining for β catenin was observed in melanoma cells 
from animals treated with AZD6244-BEZ235 compared 
to animals receiving vehicle or the PLX4720-BEZ235 
combination (Supplementary Figure 17B). 
Collectively, this evidence indicates that the 
AZD6244-BEZ235 association has an enhanced effect 
on the biological function “cell death and survival” and 
a selective modulatory effect on genes that play a role in 
melanoma resistance to target-specific inhibitors and in 
suppression of anti-tumor immunity.
DISCUSSION
Intrinsic resistance to BRAF inhibitors prevents 
~20% of melanoma patients with BRAF-mutant tumors 
from achieving clinical benefit from this type of target 
therapy and represents a major clinical issue [31, for 
review]. In this subset of patients, combination treatments 
based on co-targeting of different oncogenic pathways 
Oncotarget3959www.impactjournals.com/oncotarget
Figure 10: Selective modulation of genes in the ERK/MAPK and PI3K/AKT canonical pathways by AZD6244-BEZ235. 
(A, B) genes modulated in Me13 cells by AZD6244-BEZ235 treatment and belonging to the ERK/MAPK canonical pathway (A) and the 
PI3K/AKT canonical pathway (B). Upregulated genes are shown in red, and downregulated genes in green. Red arrows: genes differently 
affected by AZD6244-BEZ235 compared to PLX4720-BEZ235 and to AZD6244-AZD8055 treatments (see Supplementary Figure 16 for 
genes modulated by the latter two treatments). 
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have been suggested as a potentially effective approaches 
[32], but the best combinatorial association has not been 
identified yet. Clinical studies of combinatorial treatment 
with MEK and PI3K/mTOR inhibitors are ongoing in 
different solid tumors, including melanoma (source: 
www.clinicaltrials.gov) and results of published trials [33] 
suggest that dual targeting of these pathways has clinical 
activity, although toxicity issues have been identified. 
Moreover, pre-clinical studies, in different tumors suggest 
that co-targeting of MAPK and PI3K/mTOR pathways 
may be a potentially promising strategy, as shown by 
results obtained in gefitinib-resistant NSCLC cells [34], 
in pancreatic cancer cells [35], in rhabdomyosarcoma cells 
[36], in NRAS mutant melanoma cells [17] and in BRAF 
mutant melanoma cells with acquired resistance mediated 
by upregulation of PDGFRβ [16]. 
In this study we provide novel preclinical evidence 
indicating that primary resistance to BRAF inhibition 
is not only frequently associated with cross-resistance 
to MEK1/2 inhibitors, but even with cross-resistance to 
PI3K/mTOR inhibitors. Based on this evidence, we 
tested whether a combinatorial treatment approach could 
be effective in the subset of melanoma cells with the 
intrinsic cross-resistant phenotype. The results indicated 
that the most significant synergistic effects (as determined 
by combination index values) could be achieved by co-
targeting of MEK1/2 and PI3K/mTOR. Co-targeting 
of MEK1/2 and PI3K/mTOR was significantly more 
effective than BRAF and PI3K/mTOR dual blockade 
not only in-vitro, but also in-vivo, against xenografts 
from a cell line with intrinsic resistance to the BRAF 
inhibitor PLX4720. The anti-melanoma efficacy of the 
AZD6244-BEZ235 treatment was associated with strong 
inhibition of key signaling molecules, as documented by 
modulation of p-ERK and of p-AKT, both in-vitro and 
in-vivo. Interestingly, in melanoma cells with acquired 
resistance to BRAF inhibition, Shi et al. [16] found that 
PLX4720, alone or in combination with BEZ235 or 
AZD8055, induced early and delayed p-ERK recovery, 
while AZD6244 in association with BEZ235 or AZD8055, 
strongly reduced such effect. 
Assessment of the mechanism(s) involved in the 
enhanced anti-melanoma efficacy by co-targeting of 
MEK1/2 and PI3K/mTOR, compared to mutant BRAF 
and PI3K/mTOR dual inhibition, provided evidence 
for a more effective induction of apoptosis, not only 
in-vitro, but also in-vivo and even in cross-resistant 
cell lines. Treatment by AZD6244-BEZ235 was 
associated with enhanced modulation of pro- and anti-
apoptotic molecules, compared to PLX4720-BEZ235 
and to AZD6244-AZD8055. Further assessment of the 
mechanism of melanoma apoptosis, after dual pathway 
co-targeting, indicated that AZD6244-BEZ235 was the 
most effective combination at inducing activation of Bax 
and of caspase-3, the latter effect being observed both 
in-vitro and in-vivo. Silencing of Bax reduced both 
caspase-3 activation and melanoma apoptosis. Further 
assays with a pan-caspase inhibitor also indicated that 
melanoma apoptosis was significantly inhibited by a 
pan-caspase inhibitor, suggesting that one of the relevant 
effects of the combinatorial treatments is to rescue 
susceptibility of melanoma to caspase-dependent cell 
death. 
Analysis for combination-specific effects on gene 
expression, provided evidence for selective modulation 
of genes belonging to the ERK/MAPK and PI3K/AKT 
canonical pathways by the AZD6244-BEZ235, compared 
to PLX4720-BEZ235 and to AZD6244-AZD8055. The 
inhibitory effects on c-FOS, and on genes (p90RSK) 
encoding proteins that affect CREB phosphorylation, 
suggest that AZD6244-BEZ235 is a potentially effective 
approach to overcome recently described mechanisms 
mediating melanoma resistance to MAPK inhibition 
[13]. In agreement with this interpretation, caspase 3/7 
activation assays and cell death assays indicated that 
AZD6244-BEZ235 was significantly more effective in 
the promotion of apoptosis on melanoma cell lines of 
all susceptibility groups. Thus, these results support the 
notion that rescuing susceptibility to apoptosis is a major 
mechanism of action of effective co-targeting strategies 
in melanoma, as reported previously by us [18, 37–38], 
and other groups in melanoma [16] and other tumors [35]. 
The selective downmodulation of β catenin, by 
AZD6244-BEZ235 compared to PLX4720-BEZ235, 
suggests that dual blockade of the MAPK and PI3K/
mTOR pathways could suppress a recently discovered 
mechanism that melanoma cells exploit to suppress 
development of T cell mediated anti-tumor response 
[29] and provides a further rationale for the association 
of target therapy, based on dual pathway inhibition, with 
immune checkpoint blockade, an approach that has greatly 
improved the management of advanced disease [39]. 
Analysis of responsiveness to BRAF, MEK1/2 and 
PI3K/mTOR inhibitors in a few short term melanoma 
cell cultures, from patients subsequently treated with 
target therapy, suggested that drug susceptibility data 
may predict response or resistance to treatment. Clearly, 
this hypothesis needs confirmation in a larger set of 
patients, but the testing of freshly isolated melanoma cells 
from surgical samples, for responsiveness to available 
inhibitors, is feasible in principle in advanced melanoma 
and could provide a valuable evidence to inform 
subsequent clinical decisions. 
MATERIALS AND METHODS
Ethics statement
This investigation has been conducted in accordance 
with the ethical standards and according to the Declaration 
of Helsinki and according to national and international 
guidelines and has been approved by the independent 
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ethical committee of our Institute. In-vivo experiments 
in SCID mice were performed according to the Italian 
laws (D.L. 116/92 and after additions), after approval 
by the institutional Ethical Committee for Animal 
Experimentation of our Institute and by the Italian 
Ministry of Health (Project INT_17/2011).
Cell lines and short-term melanoma cell cultures
Forty-nine BRAF-mutant melanoma cell lines 
were established as described [18, 37–38, 40–41] from 
surgical specimens of American Joint Committee on 
Cancer (AJCC) stage IIIc and IV melanoma patients not 
previously subjected to target therapy. An independent 
panel of 33 short-term melanoma cell cultures was 
generated as described [40–41] from surgical samples of 
AJCC stage IIIc and IV BRAF mutant (n = 23) or wild 
type (n = 10) patients not previously subjected to target 
therapy. Short-term melanoma cell cultures were used 
between the third and fifth in-vitro passage. All patients 
were admitted to Fondazione IRCCS Istituto Nazionale 
dei Tumori, Milan and all the lesions were histologically 
confirmed to be cutaneous malignant melanomas. Informed 
consent was obtained from patients. Molecular and 
biological characterization of the cell lines and methods 
for identification of mutations in BRAF gene have been 
reported previously [18, 37–38, 41–42]. 
Treatment of melanoma cells with inhibitors and 
drug interaction analysis
Two days before treatment, melanoma cells were 
seeded in 96-wells flat bottom plates in RPMI 1640 
(BioWhittaker) supplemented with 2% fetal calf serum 
(FCS) without antibiotics. For IC50 determination, 
treatments were in quadruplicate with AZD6244 (MEK1/2 
inhibitor, SelleckChem), PLX4720 (BRAFV600E 
inhibitor, SelleckChem), BEZ235 (dual PI3K and mTOR 
inhibitor, SelleckChem), AZD8055 (dual mTORC1/2 inhibitor, 
SelleckChem). Stocks and dilutions of inhibitors were 
done in DMSO. Twelve concentrations of each inhibitor 
ranging from 1 nM to 10 μM at final FCS concentration 
of 1% were used. Cultures were evaluated at 72 hours as 
described [18, 37–38] by the 3-(4, 5) dimethylthiazol-2, 
5-diphenyltetrazolium bromide (MTT) assay. IC50 values 
were obtained through nonlinear regression analysis (by 
PRISM software, Graphpad) of dose-response curves by 
a log (inhibitor) vs. response, variable slope equation. 
Clonogenic assays were performed by seeding melanoma 
cells at single-cell density in 6-well plates. Treatments 
with AZD6244, BEZ235, PLX4720, and AZD8055 
(0.1–0.5 μM), either alone or in combination, vs. DMSO 
were done every 72 h. After 12 days, the supernatant was 
discarded, plates were washed with HBSS, fixed with 
methanol and then stained with Giemsa (Sigma Aldrich) 
followed by Image J quantification of images. Results 
of clonogenic assays were expressed as % inhibition 
of melanoma growth. For drug interaction analysis the 
Chou and Talalay method was used [24]. To this end, 
MTT assays were set up testing three combinations of 
inhibitors (AZD6244-BEZ235, PLX4720-BEZ235 and 
AZD6244-AZD8055). For each combinatorial treatment, 
twelve different combinations of doses were used. Data 
were then analyzed to obtain Combination index (CI) and 
Fraction Affected (FA) values by the CompuSyn software 
(ComboSyn). 
Antibodies and western blot analysis
Western blot analysis was carried out by the following 
antibodies specific for: AKT, p-AKT (Ser473), ERK 1/2, 
p-ERK1/2 (Thr202/Tyr204), S6, p-S6 (Ser235/236), PTEN 
and Bax (Cell Signaling); MDM4 (Bethyl Laboratories), 
MDM2 (Santa Cruz), β-actin (Sigma-Aldrich), α-tubulin 
(Calbiochem) and Vinculin (Sigma-Aldrich). SDS-PAGE 
was performed using 30  μg of protein samples on 4%–12% 
NuPAGE Bis-Tris polyacrylamide gels (Invitrogen Life 
Technologies), as described [18, 37–38]. Development 
was performed by the chemiluminescence method with the 
ECL Western Blotting Detection System (GE Healthcare) 
or Luminata Crescendo (Millipore). Basal/constitutive 
phosphoprotein characterization was carried out after 
O/N culture without FCS. Modulation of expression of 
phosphoproteins, by inhibitors, was assessed in melanoma 
cells treated either for 4 hr or O/N with MAPK and PI3K/
mTOR pathways inhibitors, alone or in combinations, 
with 2% FCS. Protein quantification was performed by 




Female SCID mice, 8–10 weeks old (Charles River 
Laboratories) were provided with food and water ad 
libitum. Melanoma cells (Me13), harvested in exponential 
growth phase, were injected s.c. (5x106) in the left flank 
of each mouse. When tumors became palpable, mice 
were randomized into three groups (7 animals/group) 
and animals received either vehicle, the association of 
AZD6244 (10 mg/kg) and BEZ235 (20 mg/Kg) or of 
PLX4720 (10 mg/Kg) and BEZ235 (20 mg/Kg), 5 days 
per week for three consecutive weeks by oral gavage. 
Mice were monitored daily for signs of toxicity and were 
weighed twice weekly. Tumor size was regularly evaluated 
by measuring the orthogonal diameters (d and D) and 




Melanoma apoptosis was assessed after staining 
with APC-conjugated Annexin V (BD Pharmingen) and 
propidium iodide (PI; BD Biosciences) as described [37–
38]. DNA content analysis was carried out after staining 
with propidium iodide (Sigma-Aldrich) as described [37]. 
Staining with purified mouse Bax conformation-specific 
antibody 6A7 or with rabbit FITC-anti-active caspase-3 
antibody (BD Pharmingen) was carried out on cells 
permeabilized with CytoFix/CytoPerm (BD Pharmingen). 
Secondary and control antibodies were, respectively, 
FITC-labeled goat anti-mouse (Jackson Immunoresearch 
Laboratories) and FITC-rabbit IgG isotype control. In 
some experiments, melanoma cells were pre-incubated 
with general caspase inhibitor z-VAD-fmk or control 
z-FA-fmk (BD Pharminge) at 5  μM for 1 h at 37°C before 
treatment with drugs. All experiments were carried out 
with a FACSCalibur flow cytometer (BD Biosciences) and 
analyzed by the FlowJo software (Tree Star). 
Cell death and caspase 3/7 activity assays by 
Muse cell analyzer
In some experiments, apoptosis and caspase 3/7 
activation were assessed by the Muse™ Cell Analyzer 
(Merck Millipore). For apoptosis determination, cells were 
collected and resuspended according to manufacturer’s 
instructions with the working solution of the Muse™ 
Annexin V & Dead Cell Kit (Merck Millipore) for 
20 minutes at room temperature. For caspase 3/7 activity 
cells were collected, resuspended in 1X Assay Buffer BA, 
and incubated with Muse™ Caspase-3/7 Assay Kit (Merck 
Millipore) reagent working solution for 30 minutes in the 
37°C incubator with 5% CO2. After incubation, Muse
™ 
Caspase 7-AAD working solution was added for 5 minutes 
at room temperature. Data were analyzed by Muse 1.4 
Analysis Software. 
Apoptosis antibody array
Melanoma cells were treated with MAPK and 
PI3K/mTOR inhibitors for 48 h. The Human Apoptosis 
Array Kit (R & D Systems) was used, as described [37] 
according to manufacturer’s instructions. The intensity of 
protein signals was quantified by densitometric analysis 
with the Quantity One software (BioRad Laboratories). 
After background subtraction, results were expressed 
as the percentage of the mean of the relative positive 
controls.
Bax silencing experiments
Transient silencing experiments were carried out 
with ON-TARGET Plus Human BAX siRNA smart-
pool (#L-003308–01–0005, Dharmacon GE Healthcare) 
containing four oligos specific for Bax (#J-003308–11, 
–12, –13, –14, Dharmacon) or corresponding negative 
control (#D-001320–10–05, Lincode non targeting 
pool, Dharmacon). Oligos were used at 10  nm final 
concentration according to Lipofectamine RNAiMAX 
guidelines (Thermo Fisher Scientific). Silencing was 
checked by Western blot analysis at 48 h and at 96 h. At 
48 h after transfection with Bax siRNA smart pool, or with 
negative control oligos, cells were treated with AZD6244 
plus BEZ235 (0.1 μM + 0.1 μM), or with PLX4720 plus 
BEZ235 (0.1 μM + 0.5 μM) and analyzed after 48 h by 
staining for Annexin-V/Propidium Iodide or for active 
caspase-3.
Immunohistochemistry
Immunohistochemistry was performed with 
formalin-fixed, paraffin-embedded tissues as described 
[40]. SCID mice bearing s.c. Me13 xenografts were 
treated with AZD6244-BEZ25 or PLX4720-BEZ235 
combinations as described for the tumor growth 
inhibition assays. Neoplastic nodules were removed 
after the last administration of inhibitors (day 31) and 
were characterized by staining with antibodies to p-ERK 
(Thr202/Tyr204, Cell Signaling), p-AKT (Ser473, Cell 
Signaling), β catenin (BD Transduction Laboratories), 
or cleaved caspase-3 (Cell Signaling). The extent of 
apoptosis in neoplastic nodules was evaluated by TUNEL 
staining (Roche). Cytospin preparations of melanoma 
cell lines were processed and stained for AXL (R & D 
Systems) and for MITF (Dako) as described [43]. Images 
were acquired at 20x with an Axiovert 100 microscope 
(Zeiss) equipped with a digital camera (AxioCam MrC5, 
Zeiss). For image acquisition, all main microscope and 
digital camera operative settings, including exposure time, 
were kept constant. Immunohistochemistry images were 
quantified using ImageJ.
Genome-wide expression profiling of melanoma 
cells treated with MAPK- and PI3K/mTOR-
specific inhibitors
Melanoma cells from Me13 cell line were treated with 
AZD6244 (0.1 μM), BEZ235 (0.1 μM), AZD8055 (0.3 μM) 
or PLX4720 (0.5 μM), or with the AZD6244-BEZ235, 
PLX4720-BEZ235, AZD6244-AZD8055 combinations for 
8 hr. Three biological replicates for each treatment were set 
up. Total RNA isolation, clean-up, DNase treatment and 
assessment of RNA integrity and purity were performed 
as described [18, 38]. Single-color hybridization of RNAs 
was performed on Illumina Bead Chip HumanHT-12_v4 
Microarrays (Illumina). The expression profiles have been 
deposited in NCBI’s Gene Expression Omnibus (GEO) 
with GSE accession number GSE59882. Background 
correction, filtering of data, and quantile normalization were 
done using the BeadStudio Illumina software. Identification 
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of significantly modulated genes was carried out by BRB 
array tools (vers 4.3.0) developed by Dr. Richard Simon and 
Amy Peng Lam. Generation of Edwards-VENN diagrams 
was obtained by VENNTURE software [26]. Downstream 
effects analysis and canonical pathway analysis were 
performed by Ingenuity Pathway analysis, IPA 8.5 (www.
ingenuity.com) as described [18].
Real time PCR
c-Fos (Hs99999140-m1), CTNNB1/β catenin 
(Hs003550489-m1) and, as endogenous control, GAPDH 
(Hs00266705-g1) TaqMan Gene Expression Assays (Applied 
Biosystems, Foster City, CA) were used. Total RNA 
(1  μg) was reverse transcribed with oligo d (t) using a 
Transcriptor First Strand cDNA Synthesis Kit (Roche, 
Penzberg, Germany). Preliminary experiments were 
conducted for the endogenous control using the Ct slope 
method to ensure that the quality of each complementary 
DNA and the dynamic range of amplifications were 
comparable [44]. Real-time PCR was then carried out 
with 20 ng input complementary DNA, 1 × TaqMan Gene 
Expression Master Mix and TaqMan Gene Expression 
Assays on a ABI PRISM 7900 HT thermal cycler (Applied 
Biosystems). Data were analyzed using ABI PRISM 
Sequence Detection Software version 2.2.2 (Applied 
Biosystems). Relative expression was determined on 
triplicate reactions using the formula 2−ΔCt, reflecting 
target gene expression normalized to endogenous control 
levels [44]. 
Statistical analysis
IC50 values were clustered by Cluster 3.0 software 
and clustering was visualized by Java TreeView. 
Correlation of susceptibility profiles to different inhibitors 
was tested by Spearman correlation analysis. Comparison 
of IC50 values, of combination index (CI) values and 
of fraction affected (FA) data, in different groups of 
melanoma cell lines, was done by Kruskal-Wallis and 
Dunn multiple comparison test. Analysis of FA values 
by combinations of inhibitors in the same group of 
melanoma cell lines, or in all cell lines, when equivalent 
doses of different inhibitors were used, was carried out 
by Wilcoxon matched pair test. Significance of different 
treatments on melanoma apoptosis, caspase activation, 
modulation of apoptosis-related molecules was assessed 
by ANOVA, followed by Student-Newman-Keul (SNK) 
multiple comparison test. Analysis of the antitumor 
activity of different treatments in-vivo was carried out by 
mixed effects model ANOVA [45] by XLSTAT software 
(Xlstat).
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